PURPOSE: To evaluate the safety and efficacy of IMC-A12, a human monoclonal antibody (mAb) that blocks insulin-like growth factor receptor-1 (IGF-1R), as monotherapy or in combination with cetuximab in patients with metastatic refractory anti-epidermal growth factor receptor (EGFR) mAb colorectal cancer. METHODS: A randomized, phase II study was performed in which patients in arm A received IMC-A12 10 mg/kg intravenously (IV) every 2 weeks, while patients in arm B received this same dose of IMC-A12 plus cetuximab 500 mg/m(2) IV every 2 weeks. Subsequently, arm C (same combination treatment as arm B) was added to include patients who had disease control on a prior anti-EGFR mAb and wild-type KRAS tumors. Archived pretreatment tumor tissue was obtained when possible for KRAS, PIK3CA, and BRAF genotyping, and immunohistochemistry was obtained for pAKT as well as IGF-1R. RESULTS: Overall, 64 patients were treated (median age, 61 years; range, 40 to 84 years): 23 patients in arm A, 21 in arm B, and 20 in arm C. No antitumor activity was seen in the 23 patients treated with IMC-A12 monotherapy. Of the 21 patients randomly assigned to IMC-A12 plus cetuximab, one patient (with KRAS wild type) achieved a partial response, with disease control lasting 6.5 months. Arm C (all patients with KRAS wild type), however, showed no additional antitumor activity. Serious adverse events thought possibly related to IMC-A12 included a grade 2 infusion-related reaction (2%; one of 64 patients), thrombocytopenia (2%; one of 64 patients), grade 3 hyperglycemia (2%; one of 64 patients), and grade 1 pyrexia (2%, one of 64 patients). CONCLUSION:IMC-A12 alone or in combination with cetuximab was insufficient to warrant additional study in patients with colorectal cancer refractory to EGFR inhibitors.
RCT Entities:
PURPOSE: To evaluate the safety and efficacy of IMC-A12, a human monoclonal antibody (mAb) that blocks insulin-like growth factor receptor-1 (IGF-1R), as monotherapy or in combination with cetuximab in patients with metastatic refractory anti-epidermal growth factor receptor (EGFR) mAb colorectal cancer. METHODS: A randomized, phase II study was performed in which patients in arm A received IMC-A12 10 mg/kg intravenously (IV) every 2 weeks, while patients in arm B received this same dose of IMC-A12 plus cetuximab 500 mg/m(2) IV every 2 weeks. Subsequently, arm C (same combination treatment as arm B) was added to include patients who had disease control on a prior anti-EGFR mAb and wild-type KRAS tumors. Archived pretreatment tumor tissue was obtained when possible for KRAS, PIK3CA, and BRAF genotyping, and immunohistochemistry was obtained for pAKT as well as IGF-1R. RESULTS: Overall, 64 patients were treated (median age, 61 years; range, 40 to 84 years): 23 patients in arm A, 21 in arm B, and 20 in arm C. No antitumor activity was seen in the 23 patients treated with IMC-A12 monotherapy. Of the 21 patients randomly assigned to IMC-A12 plus cetuximab, one patient (with KRAS wild type) achieved a partial response, with disease control lasting 6.5 months. Arm C (all patients with KRAS wild type), however, showed no additional antitumor activity. Serious adverse events thought possibly related to IMC-A12 included a grade 2 infusion-related reaction (2%; one of 64 patients), thrombocytopenia (2%; one of 64 patients), grade 3 hyperglycemia (2%; one of 64 patients), and grade 1 pyrexia (2%, one of 64 patients). CONCLUSION: IMC-A12 alone or in combination with cetuximab was insufficient to warrant additional study in patients with colorectal cancer refractory to EGFR inhibitors.
Authors: Jennifer D Wu; Austin Odman; Lily M Higgins; Kathy Haugk; Robert Vessella; Dale L Ludwig; Stephen R Plymate Journal: Clin Cancer Res Date: 2005-04-15 Impact factor: 12.531
Authors: Mark G Slomiany; Leigh Ann Black; Megan M Kibbey; Melissa A Tingler; Terry A Day; Steven A Rosenzweig Journal: Cancer Lett Date: 2006-09-22 Impact factor: 8.679
Authors: Roman K Thomas; Alissa C Baker; Ralph M Debiasi; Wendy Winckler; Thomas Laframboise; William M Lin; Meng Wang; Whei Feng; Thomas Zander; Laura MacConaill; Laura E Macconnaill; Jeffrey C Lee; Rick Nicoletti; Charlie Hatton; Mary Goyette; Luc Girard; Kuntal Majmudar; Liuda Ziaugra; Kwok-Kin Wong; Stacey Gabriel; Rameen Beroukhim; Michael Peyton; Jordi Barretina; Amit Dutt; Caroline Emery; Heidi Greulich; Kinjal Shah; Hidefumi Sasaki; Adi Gazdar; John Minna; Scott A Armstrong; Ingo K Mellinghoff; F Stephen Hodi; Glenn Dranoff; Paul S Mischel; Tim F Cloughesy; Stan F Nelson; Linda M Liau; Kirsten Mertz; Mark A Rubin; Holger Moch; Massimo Loda; William Catalona; Jonathan Fletcher; Sabina Signoretti; Frederic Kaye; Kenneth C Anderson; George D Demetri; Reinhard Dummer; Stephan Wagner; Meenhard Herlyn; William R Sellers; Matthew Meyerson; Levi A Garraway Journal: Nat Genet Date: 2007-02-11 Impact factor: 38.330
Authors: David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem Journal: N Engl J Med Date: 2004-07-22 Impact factor: 91.245
Authors: Leonard B Saltz; Neal J Meropol; Patrick J Loehrer; Michael N Needle; Justin Kopit; Robert J Mayer Journal: J Clin Oncol Date: 2004-03-01 Impact factor: 44.544
Authors: Douglas Burtrum; Zhenping Zhu; Dan Lu; Donna Marie Anderson; Marie Prewett; Daniel S Pereira; Rajiv Bassi; Rashed Abdullah; Andrea T Hooper; Henry Koo; Xenia Jimenez; Danielle Johnson; Robin Apblett; Paul Kussie; Peter Bohlen; Larry Witte; Daniel J Hicklin; Dale L Ludwig Journal: Cancer Res Date: 2003-12-15 Impact factor: 12.701
Authors: Erin R King; Zhifei Zu; Yvonne T M Tsang; Michael T Deavers; Anais Malpica; Samuel C Mok; David M Gershenson; Kwong-Kwok Wong Journal: Gynecol Oncol Date: 2011-07-02 Impact factor: 5.482
Authors: Dong Hoon Shin; Hye-Young Min; Adel K El-Naggar; Scott M Lippman; Bonnie Glisson; Ho-Young Lee Journal: Mol Cancer Ther Date: 2011-10-06 Impact factor: 6.261
Authors: Paul Haluska; Michael Menefee; Elizabeth R Plimack; Jonathan Rosenberg; Donald Northfelt; Theresa LaVallee; Li Shi; Xiang-Qing Yu; Patricia Burke; Jiaqi Huang; Jaiqi Huang; Jaye Viner; Jennifer McDevitt; Patricia LoRusso Journal: Clin Cancer Res Date: 2014-07-14 Impact factor: 12.531
Authors: Dong Hoon Shin; Hyo-Jong Lee; Hye-Young Min; Sun Phil Choi; Mi-Sook Lee; Jung Weon Lee; Faye M Johnson; Kapil Mehta; Scott M Lippman; Bonnie S Glisson; Ho-Young Lee Journal: J Natl Cancer Inst Date: 2013-10-03 Impact factor: 13.506